CoChat

Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Meister, Hanna, Look, Thomas, Roth, Patrick, Pascolo, Steve, Sahin, Ugur, Lee, Sohyon, Hale, Benjamin D., Snijder, Berend, Regli, Luca, Ravi, Vidhya M., Heiland, Dieter Henrik, Sentman, Charles L., Weller, Michael, Weiss, Tobias · 2022 · Clinical Cancer Research

Published version of a preprint

Cited by 87

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Purpose: Most chimeric antigen receptor (CAR) T-cell strategies against glioblastoma have demonstrated only modest therapeutic activity and are based on persistent gene modification strategies that have limited transgene capacity, long manufacturing processes, and the risk for uncontrollable off-tumor toxicities. mRNA-based T-cell modifications are an emerging safe, rapid, and cost-effective alternative to overcome these challenges, but are underexplored against glioblastoma. Experimental Design: We generated mouse and human mRNA-based multifunctional T cells coexpressing a multitargeting CAR based on the natural killer group 2D (NKG2D) receptor and the proinflammatory cytokines IL12 and IFNα2 and assessed their antiglioma activity in vitro and in vivo. Results: Compared with T cells that either expressed the CAR or cytokines alone, multifunctional CAR T cells demonstrated increased antiglioma activity in vitro and in vivo in three orthotopic immunocompetent mouse glioma models without signs of toxicity. Mechanistically, the coexpression of IL12 and IFNα2 in addition to the CAR promoted a proinflammatory tumor microenvironment and reduced T-cell exhaustion as demonstrated by ex vivo immune phenotyping, cytokine profiling, and RNA sequencing. The translational potential was demonstrated by image-based single-cell analyses of mRNA-modified T cells in patient glioblastoma samples with a complex cellular microenvironment. This revealed strong antiglioma activity of human mRNA-based multifunctional NKG2D CAR T cells coexpressing IL12 and IFNα2 whereas T cells that expressed either the CAR or cytokines alone did not demonstrate comparable antiglioma activity. Conclusions: These data provide a robust rationale for future clinical studies with mRNA-based multifunctional CAR T cells to treat malignant brain tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-4384

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 32

  1. Ostrom, 2020, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017, Neuro Oncol, 22, iv1, 10.1093/neuonc/noaa200 · DOI · Paper page
  2. Brown, 2016, Regression of glioblastoma after chimeric antigen receptor T-cell therapy, N Engl J Med, 375, 2561, 10.1056/NEJMoa1610497 · DOI · Paper page
  3. Ahmed, 2017, HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial, JAMA Oncol, 3, 1094, 10.1001/jamaoncol.2017.0184 · DOI · Paper page
  4. O'Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9, eaaa0984, 10.1126/scitranslmed.aaa0984 · DOI · Paper page
  5. Weiss, 2018, NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma, Cancer Res, 78, 1031, 10.1158/0008-5472.CAN-17-1788 · DOI · Paper page
  6. Yang, 2019, T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells, J Immunother Cancer, 7, 171, 10.1186/s40425-019-0642-9 · DOI
  7. Ponterio, 2020, Identification of targets to redirect CAR T cells in glioblastoma and colorectal cancer: an arduous venture, Front Immunol, 11, 565631, 10.3389/fimmu.2020.565631 · DOI
  8. Yeku, 2017, Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment, Sci Rep, 7, 10541, 10.1038/s41598-017-10940-8 · DOI · Paper page
  9. Katlinski, 2017, Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment, Cancer Cell, 31, 194, 10.1016/j.ccell.2017.01.004 · DOI · Paper page
  10. Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964 · DOI · Paper page
  11. Rafiq, 2020, Engineering strategies to overcome the current roadblocks in CAR T cell therapy, Nat Rev Clin Oncol, 17, 147, 10.1038/s41571-019-0297-y · DOI · Paper page
  12. Caruso, 2016, Redirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptor, J Immunother, 39, 205, 10.1097/CJI.0000000000000126 · DOI
  13. Baumeister, 2019, Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma, Cancer Immunol Res, 7, 100, 10.1158/2326-6066.CIR-18-0307 · DOI · Paper page
  14. Zhang, 2005, Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy, Blood, 106, 1544, 10.1182/blood-2004-11-4365 · DOI · Paper page
  15. Tusup, 2019, Design of in vitro transcribed mRNA vectors for research and therapy, Chimia, 73, 391, 10.2533/chimia.2019.391 · DOI · Paper page
  16. Weiss, 2018, NKG2D-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma, Clin Cancer Res, 24, 882, 10.1158/1078-0432.CCR-17-1766 · DOI
  17. Schuffler, 2013, TMARKER: a free software toolkit for histopathological cell counting and staining estimation, J Pathol Inform, 4, S2, 10.4103/2153-3539.109804 · DOI
  18. Friebel, 2020, Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes, Cell, 181, 1626, 10.1016/j.cell.2020.04.055 · DOI · Paper page
  19. Singer, 2016, A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells, Cell, 166, 1500, 10.1016/j.cell.2016.08.052 · DOI · Paper page
  20. Gunderson, 2020, TGFβ suppresses CD8(+) T cell expression of CXCR3 and tumor trafficking, Nat Commun, 11, 1749, 10.1038/s41467-020-15404-8 · DOI · Paper page
  21. Snijder, 2017, Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study, Lancet Haematol, 4, e595, 10.1016/S2352-3026(17)30208-9 · DOI · Paper page
  22. Etxeberria, 2019, Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8(+) T cells, Cancer Cell, 36, 613, 10.1016/j.ccell.2019.10.006 · DOI
  23. Barber, 2009, Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment, J Immunol, 183, 6939, 10.4049/jimmunol.0902000 · DOI · Paper page
  24. Zhang, 2013, Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells, J Immunol, 190, 2455, 10.4049/jimmunol.1201314 · DOI
  25. Fujita, 2010, Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans, Clin Cancer Res, 16, 3409, 10.1158/1078-0432.CCR-10-0644 · DOI
  26. Happold, 2014, Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells, Mol Cancer Ther, 13, 948, 10.1158/1535-7163.MCT-13-0772 · DOI · Paper page
  27. Lohmann, 2020, Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity, Neurooncol Adv, 2, vdaa043
  28. Wakabayashi, 2018, JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma, J Neurooncol, 138, 627, 10.1007/s11060-018-2831-7 · DOI
  29. Agliardi, 2021, Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma, Nat Commun, 12, 444, 10.1038/s41467-020-20599-x · DOI · Paper page
  30. Chiocca, 2019, Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial, Sci Transl Med, 11, eaaw5680, 10.1126/scitranslmed.aaw5680 · DOI · Paper page
  31. Vom Berg, 2013, Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection, J Exp Med, 210, 2803, 10.1084/jem.20130678 · DOI · Paper page
  32. Pohl-Guimaraes, 2019, RNA-modified T cells mediate effective delivery of immunomodulatory cytokines to brain tumors, Mol Ther, 27, 837, 10.1016/j.ymthe.2018.10.007 · DOI

Cited by

See all 87

Metadata

Authors
Meister, H., Look, T., Roth, P., Pascolo, S., Sahin, U., Lee, S., Hale, B. D., Snijder, B., Regli, L., Ravi, V. M., Heiland, D. H., Sentman, C. L., Weller, M., & Weiss, T.
Affiliations
  • 1Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • 2Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • 3Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany.
  • 4Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
  • 5Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • 6Microenvironment and Immunology Research Laboratory, Department of Neurosurgery, Medical Center, University of Freiburg, Breisgau, Germany.
  • 8Center for Synthetic Immunity and Department of Microbiology & Immunology, Geisel School of Medicine, New Hampshire.
Venue
Clinical Cancer Research
Published
2022-08-29
Volume
28
Issue
21
Pages
4747-4756
ISSN
  • 1078-0432
  • 1557-3265
Cited by
87
References
7
Language
en
Funders
  • Swiss National Science Foundation (SNF 310030_170027)
  • Swiss Cancer Research Foundation (KFS-4544-08-2018-R)
  • Forschungskredit of the University of Zurich (FK-18-054)
  • Betty and David Koetser Foundation for Brain Research
  • Promedica Stiftung
  • Helmut Horten Stiftung
  • Clinical Research Priority Program of the University of Zurich

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-4384
The paper
Meister, H., Look, T., Roth, P., Pascolo, S., Sahin, U., Lee, S., Hale, B. D., Snijder, B., Regli, L., Ravi, V. M., Heiland, D. H., Sentman, C. L., Weller, M., & Weiss, T. (2022). Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-4384

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.